Lastly, since we can block GDF15- or cisplatin-induced anorexia by neutralising the GFRAL receptor with a selective monoclonal antibody, we suggest that the anorectic responses to disease and, potentially, their therapeutic treatment may be mediated by this distinct signalling pathway. The gene discussed is GDF15; the disease is Anorexia.